ClinicalTrials.gg
CompletedNCT02365818BOND2Updated Apr 14, 2021

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

A Phase 2 interventional study of CG0070 in Bladder Cancer, sponsored by CG Oncology, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by CG Oncology, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 881 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 268 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Enrollment
281st of 714
66 · median 46
Started
2015
with 40 others
Phase 2
237 of 881
32 open now
Registered
341st of 881
by date

Among the 881 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 281st largest by enrollment of the 714 interventional ones that give a count, is one of 41 that started in 2015, is one of 237 in phase 2, and was the 341st registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 881 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 881 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.

Read the detailed description

The plan is to study the safety and efficacy of CG0070 in high-grade NMIBC (Non-muscle Invasive Bladder Cancer) patients who failed BCG therapy. Most patients with NMIBCis (Cis, Cis with Ta and/or T1, high grade Ta or T1 with frequent or uncontrolled recurrences) who have failed BCG (Bacillus Calmette-Guerin) intravesical therapy (standard of care) usually have no other choice but to proceed to cystectomy. Cystectomy is a surgery associated with major morbidity, mortality and quality of life issues. Morbidity and long term tedious medical care will be for the rest of the patient's life span. Most patients at this stage do not show signs of disease progression into the muscle layer or of metastasis, making surgery a very difficult decision. CG0070, if successful in this trial, will serve to provide a therapeutic alternative for this patient population in need.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed non-muscle invasive bladder cancer (NMIBC) high grade disease (HG), as defined by the 2004 WHO classification system
  2. Patients must have no evidence of muscle invasive disease
  3. Patients must be able to provide a sufficient sample to the central pathologist for histopathologically confirmed, transitional cell (urothelial) carcinoma. Urothelial tumors with mixed histology (but with \<50% variant) are eligible.
  4. Patients must have received at least two or more prior courses of intravesical therapy per recommended schedules. Bacillus Calmette-Guerin (BCG) must have been one of the prior therapies administered.
  5. Patients can have either failed BCG induction therapy within a six-month period or have been successfully treated with BCG, but subsequently found to have recurrence. The first standard course of intravesical BCG therapy must include at least six weekly treatments (allowable range of instillations per course is 4-9). The second course of BCG therapy must include at least two weekly treatments.
  6. Patients have either Cis or Cis with Ta and/or T1 disease at enrollment or in the past. For those patients with only Ta or T1 disease at enrollment AND with no history of Cis, they must have

    • disease recurrence either must occur within 12 months of the most recent intravesical therapy of any kind, OR
    • disease recurrence within 18 months of BCG maintenance OR
    • disease recurrence within 24 months of BCG induction
    • T1 patients need to have evidence of muscle included in their latest biopsy; and if not a re-TURBT has to be done prior to enrollment
  7. 18 years of age or older
  8. Radical cystectomy has been declined by the patient in a signed special section of the , whereby there is a clear explanation by the investigator to the subject that a delay of cystectomy may increase his/her chance of disease progression, the results of which may lead to serious and life threatening consequences.
  9. Patients must be able to enter into the study within ten weeks of their most recent diagnostic procedure, which is usually a diagnostic biopsy, a transurethral resection of bladder tumor (TURBT) procedure or positive urine cytology.
  10. (ECOG) performance status \<2.
  11. Not pregnant or lactating
  12. Patients with child bearing potential must agree to use adequate
  13. Agree to study specific informed consent and HIPAA authorization for release of personal health information
  14. Adequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000 cells/mm\^3, >1,000 cells/mm\^3, >9.5g/dL, and count >100,000 cells/mm\^3

    • Adequate renal function: serum creatinine \<2.5mg/dL
    • , and ALT not more than 2 x
    • , PTT, and fibrinogen within institutional acceptable limits
    • Absolute lymphocyte count ≥ 800/μL before the first dose of CG0070

Exclusion criteria

Exclusion Criteria:

  1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable
  2. History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, to GM-CSF or yeast derived products, allergic reactions or any known hypersensitivity or prior reaction to any of the formulation in the study drugs.
  3. Known infection with , or .
  4. Anticipated use of chemotherapy or radiotherapy not specified in the study protocol while on study
  5. Any underlying medical condition that, in the Investigator's opinion, will make the administration of study vector hazardous to the patient, would obscure the interpretation of adverse events, or not permit adequate surgical resection.
  6. Systemic treatment on any clinical trial within 28 days prior to registration.
  7. Concurrent treatment with or immunomodulatory agents, including any systemic (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ≤ 1 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.
  8. Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry.
  9. History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine) within the last year
  10. History of stage III or greater cancer, excluding urothelial cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer, must have been adequately treated and have been disease-free for ≥ 2 years at the time of registration.
  11. Progressive or persistent viral or bacterial infection

    • All infections must be resolved and the patient must remain afebrile for seven days without antibiotics prior to being placed on study
    • Urinary tract infection, including particularly bladder infection, must be resolved prior to being placed on study
  12. Unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    CG0070

    Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.

    Biological: CG0070

Interventions

  • BiologicalCG0070

    Also known as: oncolytic adenovirus with a E2F promotor and expresses GMCSF

06

What researchers measure

Primary outcomes

  1. Durable Complete Response Proportion (DCR)

    Defined as the proportion of patients who experience a durable complete response lasting 12 months or longer from the initial confirmed complete response date (first CR assessment to be at least 6 months after the first intravesical intervention) and at least 18 months from the date of the first intravesical intervention

    Time frame: 18 months time point from the date of the first intravesical intervention

Secondary outcomes

  1. Cystectomy Free Survival

    Not available, not collected on study or not currently available

    Time frame: 18 months after the first intravesical treatment

  2. Complete Response Survival

    Not available, not collected on study or not currently available

    Time frame: 18 months after the first intravesical treatment

  3. Progression Free Survival

    Not available, not collected on study or not currently available

    Time frame: 18 months after the first intravesical treatment

  4. Time to Progression to Muscle Invasive Disease

    Not available, not collected on study or not currently available

    Time frame: 18 months after the first intravesical treatment

  5. Overall Survival

    Not available, not collected on study or not currently available

    Time frame: 18 months and 24 months after first intravesical treatment

  6. PD-L1 Status Changes

    PD-L1 status of cancer cells and immune cells at tumor site by IHC

    Time frame: changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months

  7. Organ Confined Disease Proportions

    Patient proportions with no cancer cells in regional lymph nodes at cystectomy

    Time frame: at cystectomy

  8. Complete Response Proportions

    Proportions of patients with a complete response of at least 12 months' duration

    Time frame: 24 months after the first intravesical treatment

  9. PD-1 Status Changes

    PD-1 status of immune cells at tumor site by IHC

    Time frame: changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months

  10. Disease Regression Proportions

    Proportions of patients with a partial response and/or a complete response of less than 12 months' duration

    Time frame: 24 months after the first intravesical treatment

07

Study locations

17 sites
  • Alaska Clinical Research Center
    Anchorage, Alaska 99503, United States
  • BCG Oncology
    Phoenix, Arizona 85032, United States
  • Arizona Institute of Urology
    Tucson, Arizona 85704, United States
  • Institute of Urologic Oncology at UCLA
    Los Angeles, California 90095, United States
  • UC Irvine Medical Center
    Orange, California 92868, United States
  • University of California, San Diego
    San Diego, California 92093, United States
  • UF Health Cancer Center
    Gainesville, Florida 32610, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Michigan Institute of Urology, P.C.
    Troy, Michigan 48084, United States
  • Adult Pediatric Urology and Urogynecology, PC
    Omaha, Nebraska 68114, United States
  • GU Research Network/ The Urology Center
    Omaha, Nebraska 68130, United States
  • Premier Urology Group, LLC.
    Edison, New Jersey 08837, United States
  • Premier Medical Group of the Hudson Valley
    Poughkeepsie, New York 12061, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • The Urology Group
    Cincinnati, Ohio 45212, United States
  • Vanderbilt University Medical Center, Dept. of Urologic Surgery
    Nashville, Tennessee 37232, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Aug 2018, 38 months.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 38 months is close to that.

Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2015
First posted
Feb 19, 2015
StartActual
Jun 2, 2015
Primary completionActual
Aug 2018
CompletionActual
Feb 2019
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02365818
Lead sponsor
CG Oncology, Inc.
Responsible party
Sponsor
First posted
Feb 19, 2015
Start date
Jun 2, 2015
Primary completion
Aug 2018
Completion
Feb 2019
Last update
Apr 14, 2021

Study contacts

Gary Steinberg, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cretostimogene grenadenorepvec

Start the discussion